Wolverine
Wolverine is a combination sold as one vial that pairs two research peptides, BPC-157 and TB-500. The parts are studied for soft-tissue and injury recovery, mainly in animal and other preclinical work, and no controlled study has tested the pair together.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- BPC-157 / TB-500, BPC-157 / TB-500 20mg
- Recovery & tissue repair
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. All 2 sources
How much to draw
Full calculator →The reference does not report a single injectable amount for Wolverine, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Wolverine or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Pre-blended: 0.5-2.0 mg total blend daily (0.25-1.0 mg BPC-157 + 0.25-1.0 mg TB-500); Separate vials: BPC-157 250-500 mcg daily, TB-500 2.0-5.0 mg 2x/week (loading), TB-500 2.0 mg 1-2x/week (maintenance) | Pre-blended: daily; Separate vials: BPC-157 daily, TB-500 2x/week (loading) or 1-2x/week (maintenance)6-12 weeks total; loading phase weeks 1-4, maintenance phase weeks 5-8 or 5-12 depending on protocol; off-cycle gaps of 2-4 weeks commonly described | subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
| 1.0 mg total blend daily (0.5 mg of each compound) from a pre-blended 20 mg vial. | not stated | not stated | Peptide Dosing Protocols stack |
- Pre-blended: daily; Separate vials: BPC-157 daily, TB-500 2x/week (loading) or 1-2x/week (maintenance)6-12 weeks total; loading phase weeks 1-4, maintenance phase weeks 5-8 or 5-12 depending on protocol; off-cycle gaps of 2-4 weeks commonly described
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- not stated
- not stated
- Peptide Dosing Protocols stack
- Pre-blended 20 mg vial: Add 2.0 mL bacteriostatic water → 10 mg/mL total (5 mg/mL each compound); 10 units (0.10 mL) delivers 0.5 mg BPC-157 + 0.5 mg TB-500; ~20 doses per vial at 1.0 mg/day. Separate vials: Add 2.0 mL BAC water to each 10 mg vial → 5.0 mg/mL each. Steps: allow lyophilized peptide to reach room temperature; wipe both vial stoppers with alcohol swabs; draw planned BAC water volume into sterile syringe; inject BAC water against inside wall of peptide vial slowly, never directly onto powder; swirl gently until fully dissolved, do not shake; verify solution is clear (TB-500 may appear very faintly tinted); refrigerate at 35.6-46.4°F (2-8°C) and use within supplier's stated beyond-use window.
- Reconstitute with 2.0 mL BAC water for a final concentration of 10 mg/mL total blend (5 mg/mL each component).
We have not published an audit on Wolverine. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Both parts appear to support tissue repair, but in different ways: BPC-157 seems to act at the injury site, while TB-500 seems to act across the whole body. Researchers link BPC-157 to angiogenesis, the growth of new blood vessels, and to growth-factor signaling in animal models, and TB-500 to binding G-actin and helping endothelial cells, the cells that line blood vessels, move into a wound. No controlled study has tested whether the pair works better than either one alone, so the case for combining them is a hypothesis and not a proven result.
Pairs BPC-157 and TB-500 repair peptides; studied for soft-tissue and injury recovery.
Reported side effects
Seen in studies: there is no published human safety data for the combination. For BPC-157, animal studies reported low acute toxicity, and a small open-label knee-pain case series of 12 people reported no serious adverse events. For TB-500, Phase 2 trials of its full-length parent, Thymosin Beta-4, in pressure ulcers and venous stasis ulcers found no significant adverse events that differed from placebo. The TB-500 fragment itself has no completed published randomized trial.
Reported by users: redness, mild swelling, short-lived bruising and the occasional sterile abscess where it is injected, mostly put down to technique. Anecdotal reports also mention mild lethargy or head pressure during TB-500 loading phases, which no randomized trial has verified.
Not ruled out: an effect on tumors. Both parts promote new blood-vessel growth, which tumors also rely on, and a 2003 mouse study reported that Thymosin Beta-4 expression increased the spread of lung tumors. What that means for TB-500 in humans is unknown. Long-term human safety is unstudied, and independent testing of grey-market supply has found variable purity, leftover solvents and endotoxin contamination.
Who should avoid it
Athletes tested under WADA, USADA or any sport governing body: both substances are prohibited and detectable regardless of timing, so no clearance window can be assumed.
People with active or undiagnosed cancer: both parts promote new blood-vessel growth, which tumors also rely on, and a 2003 mouse study reported that Thymosin Beta-4 expression increased the spread of lung tumors. The concern is theoretical.
What gets monitored
Blood tests are mentioned (SiPhox Health At-Home Blood Test is listed as a recommended supply), but no specific labs or monitoring parameters are named on the page. (reported by peptidedosingprotocols.com)
Common questions
What is the Wolverine Stack?
It is community shorthand for pairing two research peptides, BPC-157 and TB-500, in one protocol aimed at tissue repair. It is not an FDA-approved treatment or a clinical term. The name comes from the comic-book character known for fast healing.
What is the typical Wolverine Stack dosage?
Reported amounts and schedules for Wolverine differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Should I use a pre-blended vial or separate vials?
Sources describe a trade-off between convenience and control and do not favor either format. A pre-blended vial means one daily injection at a fixed 1:1 ratio. Separate vials let BPC-157 and TB-500 run on their own schedules and amounts, and both formats deliver the same compounds.
What are the Wolverine Stack side effects?
There is no published human safety data for the combination. For the separate parts, animal studies and small human reports describe low acute toxicity, and the most common reported issue is an injection-site reaction such as redness, mild swelling or short-lived bruising. The most-cited theoretical concern is angiogenesis, the growth of new blood vessels, which is the intended repair effect but is also relevant to tumor growth.
Is BPC-157 dangerous?
Animal studies and a small open-label human knee-pain case series, covered in the Vasireddi et al. 2025 systematic review in HSS Journal, reported no serious adverse events. There is no published long-term human safety data and no completed randomized trial. The main theoretical concern is blood-vessel growth in someone with undiagnosed cancer, and the quality of unregulated supply is a separate risk.
Are BPC-157 and TB-500 FDA-approved?
No. As of June 2026, neither compound is FDA-approved. Both were removed from FDA 503A Category 2 on April 22, 2026, but neither is on Category 1. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend letting pharmacies compound each of them. The votes do not bind the FDA and are not approvals. Both remain WADA-prohibited.
How long is a typical Wolverine Stack cycle?
Community reports mostly describe 6-12 weeks in total. A common separate-vial pattern is 4 weeks of loading followed by 4-8 weeks of maintenance, while pre-blended protocols often keep one steady daily amount throughout. Gaps of 2-4 weeks between cycles are commonly described but are not formalized in any published trial.
Is there any direct evidence the Wolverine Stack works better than either peptide alone?
No. No published trial, in animals or in people, has tested the combination. The argument for synergy rests on the two peptides using different pathways, local repair for BPC-157 and body-wide cell migration for TB-500, and evidence for each part alone does not validate the pair.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.